Wikipedia -WSS

Wikipedia

author：leisure time 2025-09-28 21:06:35 - browse：3656

A sign of pharmaceutical company Bayer in front of a blossomed tree — coverage from STAT — INA FASSBENDER/AFP via Getty Images

More hopeful news on the menopause front: Bayer announced on Monday encouraging results in two Phase 3 trials for its non-hormonal drug candidate, elinzanetant, meant to treat hot flashes. The results follow the recent market launch of Veozah, Astellas Pharma’s groundbreaking non-hormonal treatment for hot flashes, which was approved by the U.S. Food and Drug Administration last spring and received approval in the U.K., under the name Veozah, in December.

Elinzanetant is a neurokinin-1 and 3 receptor antagonist, and works by calming down the estrogen receptors in the brain that become hyperactive around menopause, causing hot flashes. The drug, a pill administered once a day, was shown to reduce both the frequency and intensity of hot flashes, and also met the secondary endpoints for improving sleep and quality of life, according to JoAnn Pinkerton, professor of obstetrics and gynecology and director of the Midlife Health at UVA Health, who is a clinical investigator for Bayer’s drug candidate.

Pinkerton said she was excited to see the broader quality of life improvements through elinzanetant: “Women have more than just hot flashes — it’s actually more about hot flushes, sweats, fatigue, lack of sleep and some of the mood changes that go on during [menopause].”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： UnitedHealth CEO's Medicaid comments send insurer stocks diving

hotspot

WSS

Multiple sclerosis has subtypes with different best treatments: study

Bird flu in dairy cattle: New measures to control spread to humans

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

CMS got Medicare Advantage quality rating wrong, judge rules

Illumina board agrees to spin off Grail, as divestment plans proceed

Eli Lilly’s Zepbound improved liver scarring in mid

Wikipedia

Wikipedia

hotspot

Supreme Court strikes down use of affirmative action

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Guidelines to prevent youth baseball injuries need more muscle

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

Peter Hotez and the public health issue of online harassment

FDA approves Moderna’s RSV vaccine, its second licensed product

23andMe had bad news about my health. I wish a person had delivered it

Bird flu in dairy cattle: New measures to control spread to humans

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Wikipedia

Multiple sclerosis has subtypes with different best treatments: study

Medicare Advantage 2025 payments will dip, Biden administration says

Finland to offer bird flu vaccine to select groups of people, a possible global first

ASCO Takeaways: Winners, snoozers, and the art of cancer care

U.K. decision on ALS drug has neurologists, advocates up in arms

Illumina board agrees to spin off Grail, as divestment plans proceed

hotspot

leisure time

hotspot

entertainment